LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Akcijų sąrašas・Novartis AG

Novartis AG

Uždarymo kaina

150.46 0.06

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

150

Max

151.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	747M 3.2B
Pardavimai	189M 14B
P/E Sektoriaus vid.	21.368 49.701
Pelnas, tenkantis vienai akcijai	1.65
Dividendų pajamingumas	3.18
Pelno marža	23.336
Darbuotojai	75,267
EBITDA	338M 5.4B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+11.05% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	3.18% 2.39%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	6.3B 285B
Ankstesnė atidarymo kaina	150.4
Ankstesnė uždarymo kaina	150.46

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

N/A / 112.63 Palaikymas ir pasipriešinimas

Novartis AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-28 09:05; UTC

Uždarbis

Novartis Earnings Hit by Generic Competition -- Update

2026-04-28 05:51; UTC

Uždarbis

Novartis Could Upgrade Future Growth Outlook

2026-03-27 10:24; UTC

Įsigijimai, susijungimai, perėmimai

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

2026-03-27 06:36; UTC

Įsigijimai, susijungimai, perėmimai

Novartis to Buy Biotech Excellergy for Up to $2 Billion

2026-04-28 09:18; UTC

Rinkos pokalbiai

Uždarbis

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

2026-04-28 07:26; UTC

Rinkos pokalbiai

Uždarbis

Novartis's Results Are Mixed -- Market Talk

2026-04-28 05:07; UTC

Uždarbis

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

2026-04-28 05:05; UTC

Uždarbis

Novartis: On Track to Deliver Full-Year Guiance

2026-04-28 05:04; UTC

Uždarbis

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

2026-04-28 05:04; UTC

Uždarbis

Novartis Sees 2026 Net Sales Growing by Low Single-digit

2026-04-28 05:03; UTC

Uždarbis

Novartis 1Q Core EPS $1.99

2026-04-28 05:03; UTC

Uždarbis

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

2026-04-28 05:02; UTC

Uždarbis

Novartis 1Q Core Operating Profit $4.90B

2026-04-28 05:02; UTC

Uždarbis

Analysts Saw Novartis 1Q Sales at $13.34B

2026-04-28 05:01; UTC

Uždarbis

Novartis 1Q Sales $13.11B

2026-04-28 05:00; UTC

Uždarbis

Novartis Backs 2026 View

2026-04-28 05:00; UTC

Uždarbis

Novartis AG 1Q EPS $1.65

2026-04-28 05:00; UTC

Uždarbis

Novartis AG 1Q Net Pft $3.2B

2026-04-28 05:00; UTC

Uždarbis

Novartis AG 1Q Adj EPS $1.99

2026-04-24 05:20; UTC

Uždarbis

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

2026-04-24 05:19; UTC

Uždarbis

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

2026-04-24 05:19; UTC

Uždarbis

Novartis: Prequalification Is a Process Run by the WHO

2026-04-10 11:45; UTC

Rinkos pokalbiai

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2026-04-02 08:01; UTC

Rinkos pokalbiai

Novartis Likely to Confirm Guidance -- Market Talk

2026-03-30 09:37; UTC

Rinkos pokalbiai

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

2026-03-27 07:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

2026-03-27 06:22; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

2026-03-27 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

2026-03-27 06:04; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

2026-03-27 06:03; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Akcijų palyginimas

Kainos pokytis

Novartis AG Prognozė

Kainos tikslas

By TipRanks

11.05% į viršų

12 mėnesių prognozė

Vidutinis 167.07 USD 11.05%

Aukščiausias 180 USD

Žemiausias 141 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novartis AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Novartis AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 112.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.